Physician profile
David Marcus
NPI 1306089362
$840.74
in general payments reported to CMS, 2019-2025
24 companies · $307 in 2025
The $307 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $277 · 2020: $36.47 · 2021: $81.27 · 2022: $59.63 · 2023: $24.33 · 2024: $55.01 · 2025: $307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $386.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $386.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $183.11 | 2019-2021 | |
| Janssen Biotech, INC. | $86.53 | 2025 | Carvykti, Rybrevant |
| Astrazeneca Pharmaceuticals LP | $56.61 | 2019-2025 | Lynparza, Imfinzi |
| Regeneron Healthcare Solutions, INC. | $43.39 | 2025 | Libtayo, Lynozyfic |
| Myriad Genetic Laboratories, INC. | $38.38 | 2021 | |
| Novartis Pharmaceuticals Corporation | $38.29 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $36.41 | 2019-2025 | Keytruda, Welireg |
| Dendreon Pharmaceuticals LLC | $34.49 | 2025 | Provenge |
| Merz North America, INC. | $33.15 | 2024 | |
| Pharmacosmos Therapeutics INC. | $30.85 | 2025 | Monoferric |
| Kyowa Kirin, INC. | $28.95 | 2019 | |
| Immunocore Limited | $27.95 | 2025 | Kimmtrak |
| Palette Life Sciences, INC. | $25.39 | 2022 | |
| Eisai INC. | $24.33 | 2023 | |
| Novocure INC. | $19.03 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $18.60 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $17.17 | 2019 | |
| Seagen INC. | $16.12 | 2019 | |
| Tactile Systems Technology INC | $15.21 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $15.09 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $13.81 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.35 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.39 | 2019 | |
| Rigel Pharmaceuticals, INC. | $12.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Marcus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.